Skip to Content

'
Randall E. Millikan, PhD, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St.
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3462
Phone: 713-563-7245
Fax: 713-745-1625

Education & Training

Degree-Granting Education

1988 University of Miami, Miami, FL, MD, Medicine
1985 University of Chicago, Chicago, IL, PHD, Synthetic Organic Chemistry
1980 Wheaton College, Wheaton, IL, BS, Chemistry

Postgraduate Training

1991-1994 Clinician-Investigator Trainee in Medical Oncology, Clinician-Investigator Trainee in Medical Oncology, Mayo Clinic & Foundation, Rochester, MN
1988-1/1991 Internal Medicine, Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN
7/1985-6/1986 Postdoctoral Fellow, Synthetic Organic Chemistry, Harvard University, Cambridge, MA, Professor E. J. Corey

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1994-9/2002

Administrative Appointments/Responsibilities

Medical Director, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2003-12/2005

Institutional Committee Activities

Member, Research & Education IS Steering Team, 2005-present
Member, Clinical & Research Informatics Committee, 2005-present
Member, Clinical Research Committee, 1995-2001

Honors and Awards

2008 caBIG Teamwork Award, National Cancer Institute
1995 Career Development Award, American Cancer Society
1993 American Cancer Society Clinical Oncology Fellow, American Cancer Society
1993 Keck Fellow in Biophysical Sciences
1991 Clinician-Investigator Award in Medical Oncology, Mayo Graduate School
1990 Finalist, Associates Clinical Vignette Competition of the American College of Physicians, American College of Physicians

Selected Publications

Peer-Reviewed Original Research Articles
1. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Muller SC, Izawa JI, Ficarra V, Sagalowsky AL, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. Clin Cancer Res 16(17):441-7, 9/2010. PMID: 20651056.
2. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
3. Montero A, Diaz-Montero C, Millikan R, Liu J, Do D-A, Hodges S, Jonasch E, McIntyre B, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-(alpha): association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 6/2009. PMID: 19541791.
4. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do K-A, Logothetis CJ. Phase III trial of androgen ablation with or without 3 cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26(36):5936-42, 12/2008. PMID: 19029421.
5. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst 99(21):1613-22, 11/2007. PMID: 17971530.
6. Thall PF, Millikan RE, Meuller P, Lee SJ. Dose Finding with Two Agents in Phase 1 Oncology Trials. Biometrics 59(3):487-96, 9/2003. PMID: 14601749.
7. Millikan RE, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated Therapy for Locally Advanced Bladder Cancer. Final Report of a Randomized Trial of Cyctectomy plus Adjuvant M-VAC vs. Cystectomy with both Pre-andPost-Operative M-VAC. J Clin Oncol 19(20):4005-13, 2001.
8. Thall PF, Millikan RE, Sung H. Evaluating Multiple Treatment Courses in Clinical Trials. Stat Med 19(8):1011-28, 4/2000. PMID: 10790677.

Abstracts
1. Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S, Pagliaro LC, Dinney CP, Millikan RE. A Phase II Randomized 4-Regimen Selection Trial Incorporating Response for Sequential Chemotherapy in Metastatic, Unresectable Urothelial Cancer: Final Results from M.D. Anderson Cancer Center. 2009 Genitourinary Cancers Symposium Proceedings(238):198, 2/2009.
2. Chiong E, Taylor JM, Siefker-Radtke AO, Millikan RE, Urbauer D, McConkey DJ, Grossman HB, Dinney CP, Kamat AM. Micropappilary Bladder Cancer: Comparison of Outcomes with Up Front Cystectomy and Neoadjuvant Chemotherapy. 2009 ASCO Genitourinary Symposium Proceedings (#255), 2009.
3. Black P, Dinney CP, Brown GA, Kassouf W, Millikan RE, Siefker-Radtke AO, Munsell MF, Grossman H, Kamat AH. Radical cystoprostatectomy in patients with clinical T4b bladder cancer. 2008 ASCO Genitourinary Cancers Symposium Proceedings (#311), 2008.
4. Siefker-RAdtke AO, Kamat AM, Grossman H, Williams DL, Dinney CP, Millikan RE. Final results from a phase II trial of systemic chemotherapy in a small cell urothelial cancer: Evidence supporting neoadjuvant chemotherapy from the M. D. Anderson Cancer Center. 2007 ASCO Annual Meeting Proceedings Park I 25(18S) (#5083), 2007.
5. Rodney AJ, Siefker-Radtke A, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience. 2006 ASCO Annual Meeting Proceedings Part I 24(18S) (#14538), 2006.
6. Siefker-Radtke AO, Thall PF, Tannir NM, Tu S-M, Pagliaro LC, Williams DL, Millikan RE. Implementation of a novel statistucal design to ealuate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center. 2004 ASCO Annual Meeting Proceedings 22(14S) (#4543), 7/2004.
7. Leibovici D, Millikan RE, Grossman HB, Dinney CP, Dong Q, Wu X. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. AACR Meeting Abstracts 484 (#2105), 3/2004.
8. Tannir NM, Wang X, NGg CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Cohen L. Millikan RE. A randomized phase III Trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). 2004 ASCO Annual Meeting Proceedings 22(14S) (#4607), 2004.
9. Millikan RE, Thall P, Pagliaro L, Williams D, Brown M, Logothetis C. Randomized, adaptive, phase II selection trial of four chemotherpay regimens in androgen independent prostate cancer (AIPC). 2004 ASCO Annual Meeting Proceedings 22(14S) (#4561), 2004.

Book Chapters
1. Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: M.D. Anderson Manual of Clinical Oncology. McGraw-Hill, 739-756, 2006.
2. Siefker-Radtke A, Czerniak B, Dinney C, Millikan R. Uncommon Cancer of the Bladder. In: Texbook of Uncommon Cancer, Third Edition. Ed(s) D. Raghavan, M.L. John Wiley and Sons, 2006.
3. Millikan RE, Hall S. New Posibilities in Systemic treatment for Metastic Bladder Cancer. In: Current Clinical Oncology; Bladder Cancer: Current Diagnosis and Treatment. Humana Press Inc., 393-422, 2001.
4. Millikan RE, Thall PF. Statistical Considerations in the Phase II Evaluation of New Therapies. In: Current Clinical Urology: Bladder Cancer: Current Diagnosis and Treatment. Ed(s) Michael J. Droller. Humana Press: Totowa, NJ, 423-438, 2001.
5. Millikan RE. Carcinoma of the Prostate. In: Current Therapy in Cancer. Ed(s) John F Foley, Julie M. Vose, James O. Armitage, 175-183, 1999.
6. Agop P, Millikan RE. The University of Texas M.D. Anderson Cancer Center and The Journal Oncology Chapter. In: A Comphrensive Review. 26, 419-31, 1996.

Grant & Contract Support

Title: Specimen Core
Funding Source: NIH/NCI
Role: Co-Director
Principal Investigator: Logothetis
Duration: 7/1/2009 - 6/30/2010
 
Title: SPORE Intervention Supplement: Phase I Trial of SGT-RB94
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Dinney
Duration: 9/1/2007 - 8/31/2009
 
Title: Biostatics and Data Management Core
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Colin Dinney, MD
Duration: 9/1/2006 - 8/31/2012
 
Title: Death Receptors in Bladder Cancer progression & Therapy
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Dinney
Duration: 9/25/2001 - 8/31/2012
 
Title: Death Receptors in Bladder Cancer Progression and Therapy
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Colin P.N. Dinney
Duration: 9/25/2001 - 8/31/2006
 
Title: Biostatics & Data Management
Funding Source: NIH/NCI
Role: Co-Program Leader
Duration: 9/25/2001 - 8/31/2006
 
Title: University of Texas M.D. Anderson SPORE in Prostate Cancer
Funding Source: NIH/NCI
Role: Data Management Coordinator
Duration: 9/25/2001 - 8/31/2006
 
Title: Statistical Methods for Complex Cancer Trials
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Peter Thall, Ph.D.
Duration: 4/3/2000 - 3/31/2007

Last updated: 6/11/2012